首页|高危型人乳头瘤病毒感染与宫颈癌患者临床特征、免疫组化指标及预后的关系

高危型人乳头瘤病毒感染与宫颈癌患者临床特征、免疫组化指标及预后的关系

扫码查看
目的 探讨高危型人乳头瘤病毒(HR-HPV)感染与宫颈癌患者临床特征、免疫组化指标及预后的关系.方法 选取120例宫颈癌患者,其中HR-HPV阴性40例,HR-HPV阳性80例.比较HR-HPV阴性和HR-HPV阳性宫颈癌患者的临床特征、免疫组化指标(p16、Ki-67、p53)及预后.结果 HR-HPV阴性和HR-HPV阳性宫颈癌患者的年龄、病理类型、淋巴结转移情况、分化程度比较,差异均有统计学意义(P﹤0.05).HR-HPV阴性宫颈癌患者p16、Ki-67阳性率及5年生存率均低于HR-HPV阳性患者,差异均有统计学意义(P﹤0.05).结论 相较于HR-HPV阳性宫颈癌患者,HR-HPV阴性宫颈癌患者发病年龄更低、腺癌比例更高、更容易发生淋巴结转移、分化程度更低、p16和Ki-67阳性率更低、预后更差.
Relationship between high-risk human papilloma virus infection and clinical characteristics,immunohistochemical indicators and prognosis of cervical cancer patients
Objective To investigate the relationship between high-risk human papilloma virus(HR-HPV)infection and clinical characteristics,immunohistochemical indicators and prognosis of cervical cancer patients.Method A total of 120 patients with cervical cancer were selected,including 40 patients with HR-HPV negative and 80 patients with HR-HPV positive.The clinical characteristics,immunohistochemical indicators(p16,Ki-67 and p53)and prognosis of the pa-tients with HR-HPV positive and negative were compared.Result There were significant differences for the age,patho-logical type,lymph node metastasis and differentiation degree between HR-HPV negative patients and HR-HPV positive patients(P<0.05).The positive rates of p16 and Ki-67 and 5-year survival rate in HR-HPV negative patients were lower than those in HR-HPV positive patients,and the differences were statistically significant(P<0.05).Conclusion Com-pared with HR-HPV positive cervical cancer patients,HR-HPV negative cervical cancer patients have lower age of onset,higher proportion of adenocarcinoma,higher risk of lymph node metastasis,lower degree of differentiation,lower posi-tive rates of p16 and Ki-67,and worse prognosis.

high-risk human papilloma viruscervical cancerclinical characteristicimmunohistochemical indica-torprognosis

寇月阳、张元芬、姚德生

展开 >

广西医科大学附属肿瘤医院妇瘤科,南宁 530021

高危型人乳头瘤病毒 宫颈癌 临床特征 免疫组化指标 预后

广西自然科学基金南宁市青秀区科技计划项目

2022GXNSFAA0356482021005

2024

癌症进展
中国医学科学院,北京协和医学院

癌症进展

影响因子:1.004
ISSN:1672-1535
年,卷(期):2024.22(1)
  • 19